agree....doesnt say to much about most
investor strategy !!!!!!
- Forums
- ASX - By Stock
- NEU
- Ann: Neuren's Rett syndrome Phase 2 trial published in Neurology
NEU
neuren pharmaceuticals limited
Add to My Watchlist
1.48%
!
$13.04

Ann: Neuren's Rett syndrome Phase 2 trial published in Neurology, page-6
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$13.04 |
Change
0.190(1.48%) |
Mkt cap ! $1.598B |
Open | High | Low | Value | Volume |
$13.15 | $13.15 | $12.92 | $886.6K | 67.84K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 257 | $13.03 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.04 | 694 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 265 | 12.940 |
1 | 200 | 12.930 |
5 | 884 | 12.920 |
5 | 1289 | 12.910 |
4 | 974 | 12.900 |
Price($) | Vol. | No. |
---|---|---|
12.970 | 427 | 3 |
12.980 | 906 | 6 |
12.990 | 543 | 4 |
13.000 | 13119 | 7 |
13.010 | 928 | 6 |
Last trade - 10.14am 18/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online